Author: sugaradmin

Introduction and Objective: People with diabetes and their clinicians spend valuable time on routine visits (RV). Increasing life expectancy among people with diabetes, and an increasing incidence represents a need to restructure outpatient clinics and let technology take care of the RV using remote patient monitoring (RPM). We aim to develop an effective RPM-algorithm to […]

Introduction and Objective: To access the trustworthiness and precision of general-purpose online large language models (LLMs) in providing polycystic ovary syndrome (PCOS) diagnosis-related information.Methods: The present study recruited 125 consecutive women suspected with PCOS in the PCOS subspecialty clinic of Shanghai Tenth People’s Hospital between October 2023 and March 2024, and finally 50 women with […]

Introduction and Objective: Current treatment for obesity and pre-diabetes in older adults includes weight management and engaging in a regular exercise regimen, however, many individuals are unable to achieve success with traditional calorie restriction. Time restricted eating (TRE) is a form of intermittent fasting where individuals eat within a pre-specified daily eating window. Current trials […]

Introduction and Objective: Persistent proinsulin secretion and elevated proinsulin-to-C-peptide ratios have been reported in T1D. However, the potential of individual proinsulin proteoforms as biomarkers in T1D has not been evaluated due to the challenges associated with assay specificity. Herein, we present the first assessment of intact proinsulin, des-31,32 proinsulin, and des-64,65 proinsulin using a newly […]

Introduction and Objective: Alopecia is a potential adverse event of anti-obesity medications (AOMs). Rapid weight loss may result in deficiencies of key nutrients and act as a physiological stressor, potentially disrupting hair growth cycles and increasing hair shedding. This study aimed to evaluate the association between AOMs and risk of alopecia.Methods: PubMed, EMBASE, Cochrane Library, […]

Introduction and Objective: ASC30 is an oral GLP-1R biased small molecule agonist without β-arrestin recruitment, discovered and developed in-house at Ascletis. ASC30 has unique and differentiated properties that enable the administration of one small molecule as both a once-monthly subcutaneous injection and a once-daily oral tablet. The current study assessed safety, tolerability and pharmacokinetics of […]

Introduction and Objective: We measured the impact of online continuing medical education (CME) on knowledge and confidence of primary care physicians (PCPs) and diabetologists/endocrinologists (D/Es) on new data for using automated insulin delivery (AID) in people with T2D.Methods: The intervention comprised a 30-min online video-based discussion among 3 expert faculty with downloadable slides. Education effect […]

Introduction and Objective: Persons with type 1 diabetes (PWD) often experience nighttime fluctuations in blood glucose levels, which require active management. Those who sleep with a partner may receive instrumental support in diabetes management tasks. We examined whether partner nighttime awakenings that coincided with PWD awakenings predicted better blood glucose management following excursions.Methods: Eight emerging […]

Introduction and Objective: Ferroptosis of renal tubular epithelial cells (RTECs) is implicated in the pathogenesis of diabetic kidney disease (DKD). Bardoxolone methyl (BM), a synthetic triterpenoid with antioxidant and anti-inflammatory properties, has shown promise in clinical trials for preventing DKD-related renal decline but carries a risk of heart failure. Recent studies revealed that 2-deoxy-D-ribose (dRib) […]

Introduction and Objective: In a Phase III, randomized, placebo-controlled, multi-center study in which T2DM patients were treated with oral insulin for 26 weeks, the primary endpoint defined as a decrement of 0.6% HbA1c by end of treatment was not met. A post-hoc analysis aimed to identify subpopulations with substantial clinical responses to treatment.Methods: Explainable AI […]